Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 18;21:15330338221133224. doi: 10.1177/15330338221133224

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 6. — (A-B) Ibrutinib improved the effect of CD19 CAR-T cells in inhibiting tumor growth obviously. The tumor size reduction of the ibrutinib combined with CD19 CAR-T cell polytherapy group was greatest, and the reduction in tumor size of the zanubrutinib combined with CD19 CAR-T cell polytherapy group was slighter than the CD19 CAR-T cell monotherapy group. (C) The extinction of luciferase expression was greatest in the polytherapy group of ibrutinib with CAR-T cells than other 4 groups. (D) Ibrutinib improved CD19 CAR-T cell expansion while zanubrutinib had a slight impact on CAR-T cell expansion. Abbreviations: CD19, cluster of differentiation 19; CAR-T, chimeric antigen receptor T cell.